RxDoctor Payments Data

Shakti Mahapatra, MD

Obstetrics & Gynecology · Palm Springs, CANPI 1104822055

Payments from drug & device makers

$4,804in general payments, 2019–2025

Across 28 payments — averaging $171.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Hologic Sales And Service, LLC$286
  • Coloplast$232
  • Coopersurgical, Inc.$116
  • AMAG Pharmaceuticals, Inc.$116
  • Viiv Healthcare Company$14
  • plus $11 from 1 others

What the payments were for

  • Speaking & faculty fees$2,40050%
  • Travel & lodging$97820%
  • Food & beverage$1,31027%
  • Education$1162%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,804 in reported general payments places this provider in the 85th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$77,389
Medicare patients
341
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol237$18,351
PremarinEstrogens, Conjugated36$16,994
IntrarosaPrasterone (Dhea)14$7,605
VeozahFezolinetant11$6,875
ImvexxyEstradiol14$5,916
YuvafemEstradiol27$5,455
Estradiol (Twice Weekly)Estradiol46$4,050
Estradiol (Once Weekly)Estradiol26$2,408
ProgesteroneProgesterone, Micronized63$2,226
DottiEstradiol22$1,149
ValacyclovirValacyclovir Hcl17$747
Clobetasol Propionate16$503
Raloxifene Hcl11$391
Medroxyprogesterone Acetate22$219
Alendronate Sodium24$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AMAG Pharmaceuticals, Inc.Intrarosa$116$7,60514 claims
Therapeuticsmd, Inc.Imvexxy$11$5,91614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →